Effect of fluvoxamine on cytokine in COVID-19 patients

Effect of fluvoxamine medicine on cytokine level of COVID-19 patients, hospitalized in ICU ward

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20131115015405N4

Enrollment

Registered

2020-10-03

Start date

2020-07-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: This group will be treated by Fluvoxamine drug. The drug dosage will be increased up to 300 mg daily depending on the patients tolerance to the drug. At first, 50 m

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Informed consent Being conscious Definite diagnosis of COVID-19 in medical records of the patient Age over 18 years old Normal serum level of Creatinine, Blood Ureh Nitrogen, White Blood Cell, Potassium, Sodium and Fasting Blood Sugar

Exclusion criteria

Exclusion criteria: Being pregnant. Existence of ASA, Warfarin, MAOI, Lithium, Clomipramine, NSAIDs, Methadone, Capropril, Diltiazem and Zolpidem drugs in medical files of the patient. Simultaneous consumption of any kind of alcohol or substance.

Design outcomes

Primary

Measure	Time frame
Interlukine - 6 (IL-6) level will be measured in COVID-19 patients. Timepoint: The Interlukine - 6 level will be measured both before the consumption of Fluvoxamine drug and when discharging from the ICU ward. Method of measurement: Measuring kit of Interlukine - 6 by blood test.;Erythrocyte Sedimentation Rate (ESR) level will be measured in COVID-19 patients. Timepoint: The Erythrocyte Sedimentation Rate (ESR) level will be measured both before the consumption of Fluvoxamine drug and when discharging from the ICU ward. Method of measurement: Measuring kit of Erythrocyte Sedimentation Rate (ESR) by blood test.;C-Reactive Protein (CRP) level will be measured in COVID-19 patients. Timepoint: The C-Reactive Protein (CRP) level will be measured both before the consumption of Fluvoxamine drug and when discharging from the ICU ward. Method of measurement: Measuring kit of C-Reactive Protein (CRP) by blood test.	—

Measure

Time frame

Interlukine - 6 (IL-6) level will be measured in COVID-19 patients. Timepoint: The Interlukine - 6 level will be measured both before the consumption of Fluvoxamine drug and when discharging from the ICU ward. Method of measurement: Measuring kit of Interlukine - 6 by blood test.;Erythrocyte Sedimentation Rate (ESR) level will be measured in COVID-19 patients. Timepoint: The Erythrocyte Sedimentation Rate (ESR) level will be measured both before the consumption of Fluvoxamine drug and when discharging from the ICU ward. Method of measurement: Measuring kit of Erythrocyte Sedimentation Rate (ESR) by blood test.;C-Reactive Protein (CRP) level will be measured in COVID-19 patients. Timepoint: The C-Reactive Protein (CRP) level will be measured both before the consumption of Fluvoxamine drug and when discharging from the ICU ward. Method of measurement: Measuring kit of C-Reactive Protein (CRP) by blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMitra Safa

Shahid Beheshti University of Medical Sciences

mitra.safa@yahoo.com+98 21 2712 2607

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026